Paper Details

  1. Home
  2. Paper Details

Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: A randomized study.

Author: CarneiroJorge David Aivazoglou, D'AmicoElbio Antonio, LopesMarta Heloisa, NakasoneMayumi, SandovalEliane Partite Nobre, SartoriAna Marli Chritovam, VillaçaPaula Ribeiro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Hepatitis A vaccine administered subcutaneously was found to be as immunogenic and protective as the intramuscular route in patients with hemophilia and other bleeding disorders. Furthermore, the subcutaneous route was found to be safer.
Paper Details　
Original Abstract of the Article :
Hepatitis A vaccine is recommended for all individuals with hemophilia, although patients with bleeding disorders should avoid intramuscular (IM) injections. To date, only few studies showed subcutaneous (SC) route immunogenicity is comparable with the IM route. Therefore, this randomized study comp...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2020.04.040

データ提供：米国国立医学図書館（NLM）

A Safe and Effective Alternative: Subcutaneous Hepatitis A Vaccine

The field of immunology is constantly evolving, with researchers striving to improve the safety and efficacy of vaccines. This research focuses on the safety and immunogenicity of subcutaneous administration of hepatitis A vaccine in individuals with hemophilia and other bleeding disorders. This study offers a promising alternative to traditional intramuscular injections, which can pose risks for these patients.

Subcutaneous Hepatitis A Vaccine: A Viable Option for Hemophilia Patients

The study demonstrates that subcutaneous administration of hepatitis A vaccine is as immunogenic and protective as the intramuscular route, with a lower risk of bleeding complications. This finding is particularly significant for individuals with hemophilia, who often face challenges with traditional intramuscular injections. The results suggest that subcutaneous vaccination is a safe and effective option for this vulnerable population.

Protecting Against Hepatitis A: A Safer Approach

This research has important implications for individuals with hemophilia and other bleeding disorders, offering them a safer and more convenient option for hepatitis A vaccination. The study's findings contribute to the ongoing efforts to enhance vaccine safety and accessibility, ensuring that all individuals have access to effective protection against preventable diseases.

Dr.Camel's Conclusion

This study is like a cool breeze in a hot desert, offering a refreshing alternative to traditional vaccination approaches. The findings demonstrate that subcutaneous administration of hepatitis A vaccine is a safe and effective option for individuals with hemophilia, providing them with the same level of protection without the added risks of intramuscular injections. This is a testament to the power of scientific research and its potential to improve health outcomes for all.

Date :
  1. Date Completed 2021-03-15
  2. Date Revised 2021-03-15
Further Info :

Pubmed ID

32376110

DOI: Digital Object Identifier

10.1016/j.vaccine.2020.04.040

Related Literature

Article Analysis
・Effects of hepatitis a vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.